The Potential for Intermediate Clinical Endpoints as Surrogates for Overall Survival
Renee Maria Saliby, a research fellow at Dana-Farber Cancer Institute, presented research exploring the use of intermediate clinical endpoints as surrogates for overall survival in patients with metastatic renal cell carcinoma receiving immune checkpoint-based regimens.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
